Zhang Hongyu, Deng Mi, Pei Fen, Wang Shouye, Ho Mitchell
Department of Biochemical Engineering, University College London, London, WC1E 6BT, UK.
Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Antib Ther. 2019 Oct;2(4):99-107. doi: 10.1093/abt/tbz012. Epub 2019 Dec 10.
The Chinese Antibody Society (CAS) convened the third annual conference in Cambridge, Massachusetts, USA on April 7, 2019. More than 600 global members attended the meeting. The theme of this conference was Next-Generation Antibody Therapeutics: Discovery, Development and Beyond. The meeting covered a vast variety of topics including cancer immunotherapy, single-domain antibodies as well as bispecific antibodies, immunotoxins, transgenic mouse platforms for next-generation monoclonal antibody discovery and antibody chemistry, manufacturing and controls (CMCs). Two hot topics were comprehensively discussed by the prestigious panelists and hosts at the panel discussions during the conferences, i.e., bispecific antibodies and antibody CMC.
中国抗体协会（CAS）于2019年4月7日在美国马萨诸塞州剑桥市召开了第三届年会。600多名全球会员参加了此次会议。本次会议的主题是“下一代抗体疗法：发现、开发及未来”。会议涵盖了广泛的主题，包括癌症免疫疗法、单域抗体以及双特异性抗体、免疫毒素、用于下一代单克隆抗体发现的转基因小鼠平台以及抗体化学、生产与控制（CMC）。在会议期间的小组讨论中，知名专家和主持人对两个热门话题进行了全面讨论，即双特异性抗体和抗体CMC。
